Neumora Therapeutics Inc (NMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.31-2.96%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NMRA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||
| R&D Expenses | 153.1 | 176.1 | 200.9 | 142.7 | 91.7 | — |
| Operating Income | (211.2) | (241.2) | (263.5) | (252.1) | (135.9) | — |
| Earnings from Continuing Operations | ||||||
| Interest Expense | — | 3.2 | — | — | — | — |
| Interest & Investment Income | 5.2 | 8.3 | — | — | — | — |
| Other Non-Operating Income / Expenses | (1.5) | 4.4 | 19.9 | 16.4 | 5.0 | — |
| EBT, Incl. Unusual Items | (212.7) | (236.8) | (243.6) | (235.7) | (130.9) | — |
| Income Tax Expense | — | 0.1 | 0.2 | 0.3 | — | — |
| Net Income | ||||||
| Net Income | 261.1 | (236.9) | (243.8) | (235.9) | (130.9) | — |
| Per Share | ||||||
| Basic EPS | 1.41 | (1.45) | (1.53) | (3.63) | (4.81) | — |
| Diluted EPS | 1.41 | (1.45) | (1.53) | (3.63) | (4.81) | — |
| Basic Weighted Avg Shares | 185.2 | 163.4 | 159.4 | 65.0 | 27.2 | — |
| Diluted Weighted Avg Shares | 185.2 | 163.4 | 159.4 | 65.0 | 27.2 | — |
| Supplemental | ||||||
| EBITDA | — | (240.9) | (262.8) | (251.4) | (135.3) | — |
| EBIT | (211.2) | (241.2) | (263.5) | (252.1) | (135.9) | — |
| Effective Tax Rate | — | — | — | -0.1% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.